Table 1 Baseline demographic and clinical characteristics of 39 evaluated patients with gemcitabine-refractory advanced pancreatic cancer
Characteristic | No. of patients | % |
|---|---|---|
Age | ||
≤ 60 years | 25 | 64.1 |
> 60 years | 14 | 35.9 |
Sex | ||
Male | 29 | 74.4 |
Female | 10 | 25.6 |
ECOG PS | ||
0 | 2 | 5.1 |
1 | 35 | 89.7 |
2 | 2 | 5.1 |
Extent of disease | ||
Locally advanced | 7 | 17.9 |
Metastatic | 32 | 82.1 |
Primary tumor location | ||
Head | 18 | 46.1 |
Body | 9 | 23.1 |
Tail | 12 | 30.8 |
Metastatic site | ||
Liver | 17 | 43.6 |
Lung | 7 | 17.9 |
Distant lymph nodes | 14 | 35.9 |
Peritoneum | 7 | 17.9 |
Multiple organs | 13 | 33.3 |
CA19-9 value (U/mL) | ||
> 10 times of UNL | 21 | 53.8 |
≤ 10 times of UNL | 18 | 46.2 |
Patients who received 3rd line chemotherapy | 12 | 30.8 |